Fintwit Blog
Actionable investing insights, AI-powered stock research, and tips to help you make smarter investment decisions.
Featured · AI for Investing
11 copy-paste ChatGPT prompts for equity research, plus a better alternative at half the price.
11 Claude prompts for equity research and earnings analysis, plus an automated alternative.
11 Gemini prompts for equity research, plus how Fintwit automates the whole flow.
Latest
NVIDIA (NVDA) remains the foundational architect of global AI. We break down the financials, competitive moat, and the latest analyst sentiment.
AutoZone reports Q3 2026 earnings on May 26. We break down the consensus estimates, key segment growth, and the impact of LIFO charges on margins.
Zscaler enters Q3 with raised ARR guidance. We analyze the key metrics, analyst sentiment, and the path forward for the cybersecurity leader.
Zscaler enters Q3 with 40 upward EPS revisions. We analyze the key metrics, competitive pressures, and management guidance ahead of the May 26 report.
Third Point's Q1 2026 13F shows Daniel Loeb exiting Microsoft and slashing NVIDIA to rotate into Meta, Alphabet, and Lam Research.
Astera Labs (ALAB) is up over 200% in a year. Is the AI infrastructure play still a buy at a 100x P/E ratio?
Guardant Health shares surged 17% on strong Q1 results. We break down the bull and bear cases for this high-growth diagnostics player.
Abivax (ABVX) approaches its May 25 earnings report with eyes on Phase 3 clinical milestones and a potential U.S. NDA filing in late 2026.
Abivax enters Q1 2026 with strong analyst backing. We break down the clinical milestones and financial metrics to watch ahead of the May 25 report.
Get smarter investing insights, free.
Join thousands of investors using Fintwit for AI stock analysis, real-time signals from X, and curated daily picks.
Free to start. Premium just $9.99/mo.